April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Toxicological Evaluation of Preservative-Containing and Preservative-Free Prostaglandin Analogs on the 3d-Reconstituted Corneal Epithelium (SkinethicTM) System
Author Affiliations & Notes
  • F. Brignole-Baudouin
    Toxicologie, Faculte de Pharmacie, Paris, France
    INSERM, UMRS 968, Vision Institut, UPMC, Paris, France
  • H. Liang
    INSERM, UMRS 968, Vision Institut, UPMC, Paris, France
    Department of Ophthalmology, Quinze-Vingts National Ophthalmology Hospital, Paris, France
  • A. Pauly
    INSERM, UMRS 968, Vision Institut, UPMC, Paris, France
  • L. Riancho
    INSERM, UMRS 968, Vision Institut, UPMC, Paris, France
  • C. Baudouin
    INSERM, UMRS 968, Vision Institut, UPMC, Paris, France
    Department of Ophthalmology, Quinze-Vingts National Ophthalmology Hospital, Paris, France
  • Footnotes
    Commercial Relationships  F. Brignole-Baudouin, None; H. Liang, Research Funding, F; A. Pauly, None; L. Riancho, None; C. Baudouin, Consultant, C.
  • Footnotes
    Support  Vision Institut, Paris, France
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 2371. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      F. Brignole-Baudouin, H. Liang, A. Pauly, L. Riancho, C. Baudouin; Toxicological Evaluation of Preservative-Containing and Preservative-Free Prostaglandin Analogs on the 3d-Reconstituted Corneal Epithelium (SkinethicTM) System. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2371.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Using an established three-dimensional (3D) toxicological model based on reconstituted human corneal epithelium (HCE), this study investigated the tolerability of four topical intraocular pressure (IOP)-lowering agents: the commercial solutions of 0.005% latanoprost, 0.004% travoprost, 0.03% bimatoprost containing 0.02%, 0.015%, and 0.005% benzalkonium chloride (BAC), respectively and the preservative-free (PF) tafluprost. Solutions of 0.01% and 0.02%BAC alone were also evaluated for comparison.

Methods: : The 3D-HCEs were treated with the test solutions for 24 hours followed or not by a 24-hour recovery period. We used a modified MTT procedure to assess cell viability in the HCEs. Frozen sections were analyzed using fluorescence microscopy for the evaluation of apoptosis (TUNEL), inflammation (ICAM-1), and proliferation (Ki67). Corneal epithelial tight junctions (occludin and ZO-1) were also assessed by en-face confocal microscopy in response to the different eye drops.

Results: : The MTT test revealed the cytotoxicity of these antiglaucoma eye drops that was primarily related to the concentration of their common BAC preservative (0.02%BAC-latanoprost > 0.015%BAC-travoprost > 0.005%BAC-bimatoprost). PF-tafluprost did not induce obvious cytotoxicity and showed the least expression of inflammatory or apoptotic markers and revealed preservation of membrane immunostaining of tight junction proteins in comparison with BAC-containing solutions.

Conclusions: : The toxicological model of 3D reconstructed corneal epithelium model confirmed the ocular surface cytotoxicity of BAC-containing antiglaucomatous solutions. Compared to the formulations containing the BAC, in this 3D model, PF-tafluprost was well tolerated without inducing significant corneal epithelium deterioration.

Keywords: cornea: epithelium • drug toxicity/drug effects • ocular irritancy/toxicity testing 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×